RecruitingPhase 2NCT02781883
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Studying Inherited acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bio-Path Holdings, Inc.
- Principal Investigator
- Maro Ohanian, DOM.D. Anderson Cancer Center
- Intervention
- BP1001 in combination with Ventoclax plus decitabine(drug)
- Enrollment
- 108 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2028
Study locations (9)
- UCLA Medical Center, Los Angeles, California, United States
- Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
- University of Kansas Cancer Center, Fairway, Kansas, United States
- New Jersey Hematology Oncology Associates, Brick, New Jersey, United States
- Laura & Isaac Pe lmutter Cancer Center at NYU Langone Health, New York, New York, United States
- Weill Cornell Medical College - New York - Presbyterian Hospital, New York, New York, United States
- University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
- Baylor Scott & White Research Institute, Temple, Texas, United States
- West Virginia University/Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02781883 on ClinicalTrials.govOther trials for Inherited acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06782542Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyJustin Watts, MD
- RECRUITINGPHASE2NCT06557421De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07130695Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and ConsolidationVirginia Commonwealth University
- RECRUITINGPHASE1NCT07320235Imetelstat Combinations in Relapsed AMLDouglas Tremblay
- RECRUITINGPHASE2NCT06904482Co-Transplant of an Unmodified Haplo-Identical Graft With Cord BloodCase Comprehensive Cancer Center
- RECRUITINGNCT07163728Leptin: A Marker for AML Chemo-SensitivityFujian Medical University Union Hospital
- RECRUITINGNANCT06697600A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their CaregiversUniversity of Rochester
- RECRUITINGPHASE2, PHASE3NCT06972641Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRuijin Hospital